---
title: "60 Degrees Pharmaceuticals 1Q 2026: Revenue $162.09K, EPS ($1.28) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286564505.md"
description: "60 Degrees Pharmaceuticals reported Q1 2026 revenue of $162.09K, nearly flat compared to $163.55K last year, with a net loss of $2.21M or $1.28 per share. U.S. distributor sales accounted for 90% of revenue, despite a 19% decline in volume. The company launched GoodRx listings and partnered with Runway Health. A babesiosis trial showed 100% cure rate, and an NDIN for Australian Chestnut Extract was submitted to the FDA."
datetime: "2026-05-15T12:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286564505.md)
  - [en](https://longbridge.com/en/news/286564505.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286564505.md)
---

# 60 Degrees Pharmaceuticals 1Q 2026: Revenue $162.09K, EPS ($1.28) — 10-Q Summary

60 Degrees Pharmaceuticals reported first-quarter 2026 results showing essentially flat product revenue of $162.09K versus $163.55K a year earlier, and a net loss attributable to common stockholders of ($2.21M) or ($1.28) per diluted share.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$162.09K

$163.55K

(0.9%)

Net income²

($2.21M)

($2M)

(10.2%)

Diluted EPS³

($1.28)

($6.25)

79.5%

_¹ Reported as “Product Revenues – net of Discounts and Rebates”. ² Reported as “Net Loss - attributed to common stockholders”. ³ Reported as “Loss per Common Share (1)”._

**Business Highlights**

-   Revenue and channel mix: Product revenue held steady year‑over‑year at roughly $162K, with U.S. distributor sales representing about 90% of sales; U.S. volume declined 19% versus the prior year.
-   Commercial initiatives: Launched GoodRx discount listings and a partnership with Runway Health telehealth to expand pre‑departure access and patient savings for Arakoda.
-   Clinical and regulatory progress: A babesiosis trial reported 3/3 patients cured with tafenoquine; an NDIN for Australian Chestnut Extract was submitted to the FDA, with no‑objection timing noted by May 25, 2026.
-   Packaging and supply: The company moved to an 8‑count bottle format (reported as 16‑count box equivalents) to reduce per‑unit packaging costs, while incurring higher storage with its U.S. packager.

Original SEC Filing: 60 DEGREES PHARMACEUTICALS, INC. \[ SXTP \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SXTPW.US](https://longbridge.com/en/quote/SXTPW.US.md)
- [SXTP.US](https://longbridge.com/en/quote/SXTP.US.md)
- [GDRX.US](https://longbridge.com/en/quote/GDRX.US.md)

## Related News & Research

- [Alaunos Reports Preclinical Aln1003 Data Showing Effects On Insulin-Resistance-Related Biomarkers And Liver Histology In Diet-Induced Obesity Models](https://longbridge.com/en/news/286776760.md)
- [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md)
- [Dollar could fall if risk appetite improves](https://longbridge.com/en/news/285961244.md)
- [Wall Street's Most Accurate Analysts Spotlight On 3 Risk Off Stocks With Over 6% Dividend Yields](https://longbridge.com/en/news/286407235.md)
- [Littelfuse unveils 2030 ambition, $4.5B revenue target and Basler deal adds $130M–$135M revenue](https://longbridge.com/en/news/286413007.md)